Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer

Open access

Published version of a preprint

Abstract

The cornerstone of treatment for advanced ALK-positive lung cancer is sequential therapy with increasingly potent and selective ALK inhibitors. The third-generation ALK inhibitor lorlatinib has demonstrated clinical activity in patients who failed previous ALK inhibitors. To define the spectrum of ALK mutations that confer lorlatinib resistance, we performed accelerated mutagenesis screening of Ba/F3 cells expressing EML4–ALK. Under comparable conditions, N-ethyl-N-nitrosourea (ENU) mutagenesis generated numerous crizotinib-resistant but no lorlatinib-resistant clones harboring single ALK mutations. In similar screens with EML4–ALK containing single ALK resistance mutations, numerous lorlatinib-resistant clones emerged harboring compound ALK mutations. To determine the clinical relevance of these mutations, we analyzed repeat biopsies from lorlatinib-resistant patients. Seven of 20 samples (35%) harbored compound ALK mutations, including two identified in the ENU screen. Whole-exome sequencing in three cases confirmed the stepwise accumulation of ALK mutations during sequential treatment. These results suggest that sequential ALK inhibitors can foster the emergence of compound ALK mutations, identification of which is critical to informing drug design and developing effective therapeutic strategies. Significance: Treatment with sequential first-, second-, and third-generation ALK inhibitors can select for compound ALK mutations that confer high-level resistance to ALK-targeted therapies. A more efficacious long-term strategy may be up-front treatment with a third-generation ALK inhibitor to prevent the emergence of on-target resistance. Cancer Discov; 8(6); 714–29. ©2018 AACR. This article is highlighted in the In This Issue feature, p. 663

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-17-1256

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Cited by

See all 326

Metadata

Authors
Yoda, S., Lin, J. J., Lawrence, M. S., Burke, B. J., Friboulet, L., Langenbucher, A., Dardaei, L., Prutisto-Chang, K., Dagogo-Jack, I., Timofeevski, S., Hubbeling, H., Gainor, J. F., Ferris, L. A., Riley, A. K., Kattermann, K. E., Timonina, D., Heist, R. S., Iafrate, A. J., Benes, C. H., Lennerz, J. K., Mino-Kenudson, M., Engelman, J. A., Johnson, T. W., Hata, A. N., & Shaw, A. T.
Affiliations
  • Harvard University (US)
  • Broad Institute (US)
  • Pfizer (United States) (US)
  • Inserm (FR)
  • Massachusetts General Hospital (US)
  • 1Massachusetts General Hospital Cancer Center, Charlestown, Massachusetts.
  • Novartis (Switzerland) (CH)
Venue
Cancer Discovery
Published
2018-05-31
Volume
8
Issue
6
Pages
714-729
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2797685139
Cited by
322
References
42
Citations by year
2026: 33 · 2025: 32 · 2024: 41 · 2023: 34 · 2022: 42 · 2021: 49 · 2020: 37 · 2019: 35 · 2018: 19
FWCI
26.56
Type
journal article
Language
en
Open access
Locations
  • Cancer Discovery (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • HAL (submittedVersion, other-oa)
Funders
  • HHS | NIH | National Cancer Institute (NCI) (R01CA164273)
  • American Association for Cancer Research (AACR) (17-40-12-DARD)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords
ALK-positive lung cancer, lorlatinib resistance, EML4-ALK fusion, crizotinib resistance, N-ethyl-N-nitrosourea mutagenesis, Ba/F3 cells
MeSH terms
Exome Sequencing, Crizotinib, Anaplastic Lymphoma Kinase, Aminopyridines, Animals, Ethylnitrosourea, Female, Humans, Lactams, Lung Neoplasms, Mutation, Pyrazoles, Oncogene Proteins, Fusion, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Cell Line, Tumor, Lactams, Macrocyclic, Protein Kinase Inhibitors, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer. https://app.cochat.ai/papers/10.1158/2159-8290.cd-17-1256
The paper
Yoda, S., Lin, J. J., Lawrence, M. S., Burke, B. J., Friboulet, L., Langenbucher, A., Dardaei, L., Prutisto-Chang, K., Dagogo-Jack, I., Timofeevski, S., Hubbeling, H., Gainor, J. F., Ferris, L. A., Riley, A. K., Kattermann, K. E., Timonina, D., Heist, R. S., Iafrate, A. J., Benes, C. H., . . . Shaw, A. T. (2018). Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-17-1256

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.